{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:27:01Z","timestamp":1791559621504,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","award":["2023-13450"],"award-info":[{"award-number":["2023-13450"]}],"id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Microwave ablation (MWA) with higher-power settings (&gt;\u2009100\u00a0W) aims to create larger, more uniform ablation zones, potentially reducing local tumour progression (LTP). This post-market clinical follow-up study evaluated the safety and efficacy of higher-power settings for MWA of liver tumours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with colorectal liver metastases (CRLM) and hepatocellular carcinoma (HCC) treated with MWA (&gt;\u2009100\u00a0W) using the EMPRINT\n                      <jats:sup>TM<\/jats:sup>\n                      HP generator (Medtronic, Minneapolis, MN, USA) were included. The primary outcome measure was safety, assessed by CTCAE. Higher-power settings were considered safe if complication rates did not exceed those of a historical cohort treated with conventional settings (EMPRINT\u2122;\u2009\u2264\u2009100\u00a0W). Secondary outcome measures included LTP-free survival (LTPFS), local control (LC), sphericity index (SI) and length of hospital-stay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One-hundred-and-twenty-three patients were included. Following 97 procedures for CRLM (82 patients), adverse events (AEs) occurred in 13.4%, with serious AEs (SAEs) in 4.1%. In 44 procedures for HCC (41 patients), AEs occurred in 11.4%, with SAEs in 6.8%. The total SAE rate (5.0%) was lower than the historical cohort (5.8%). For CRLM and HCC, 1-, 2-, and 3-year LTPFS was 94.9%, 93.7%, 93.7%, and 95.1%, 92.5%, 92.5%, respectively. LTP occurred in 4.8% of CRLM (vs. 6.9% in historical cohort;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.38) and in 6.3% of HCC. LC was 100%. Median hospital-stay was 1 day. Median SI was 0.79 for both CRLM and HCC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study indicates that higher-power settings (&gt;\u2009100\u00a0W) during MWA for liver tumours does not compromise safety or sphericity of the ablation zone. This was supported by low LTP rates and 100% local control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence<\/jats:title>\n                    <jats:p>Level 3<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00270-025-04228-y","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:58:53Z","timestamp":1760558333000},"page":"289-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Efficacy of High Power (&gt;\u2009100W) Microwave Ablation Using the EMPRINT\u2122 HP System: Final Results of a Post-Market Clinical Follow-Up Study"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6413-476X","authenticated-orcid":false,"given":"Susan","family":"van der Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"van der Wal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Neuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Ambrosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah H.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle J. W.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelon","family":"Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentine E. F.","family":"Timmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert S.","family":"Puijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn R.","family":"Meijerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"4228_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx015","author":"T Ruers","year":"2017","unstructured":"Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017. https:\/\/doi.org\/10.1093\/jnci\/djx015.","journal-title":"J Natl Cancer Inst"},{"key":"4228_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102926","volume":"136","author":"G Bregni","year":"2025","unstructured":"Bregni G, Adams R, Bale R, Bali MA, Bargellini I, Blomqvist L, et al. EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases. Cancer Treat Rev. 2025;136:102926.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"4228_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10\u201332.","journal-title":"Ann Oncol"},{"issue":"2","key":"4228_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(24)00660-0","volume":"26","author":"S van der Lei","year":"2025","unstructured":"van der Lei S, Puijk RS, Dijkstra M, Schulz HH, Vos DJW, De Vries JJJ, et al. Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial. Lancet Oncol. 2025;26(2):187\u201399.","journal-title":"Lancet Oncol"},{"key":"4228_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-022-03152-9","author":"RS Puijk","year":"2022","unstructured":"Puijk RS, Dijkstra M, van den Bemd BAT, Ruarus AH, Nieuwenhuizen S, Geboers B, et al. Improved outcomes of thermal ablation for colorectal liver metastases: a 10-year analysis from the prospective Amsterdam CORE registry (AmCORE). Cardiovasc Intervent Radiol. 2022. https:\/\/doi.org\/10.1007\/s00270-022-03152-9.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"8","key":"4228_CR6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00270-018-1959-3","volume":"41","author":"MR Meijerink","year":"2018","unstructured":"Meijerink MR, Puijk RS, van Tilborg A, Henningsen KH, Fernandez LG, Neyt M, et al. Radiofrequency and microwave ablation compared to systemic chemotherapy and to partial hepatectomy in the treatment of colorectal liver metastases: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2018;41(8):1189\u2013204.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4228_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejca.2023.03.038","volume":"187","author":"P Tinguely","year":"2023","unstructured":"Tinguely P, Ruiter SJS, Engstrand J, de Haas RJ, Nilsson H, Candinas D, et al. A prospective multicentre trial on survival after microwave ablation versus resection for resectable colorectal liver metastases (MAVERRIC). Eur J Cancer. 2023;187:65\u201376.","journal-title":"Eur J Cancer"},{"issue":"3","key":"4228_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"4","key":"4228_CR9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jhep.2017.10.004","volume":"68","author":"JC Nault","year":"2018","unstructured":"Nault JC, Sutter O, Nahon P, Ganne-Carrie N, Seror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol. 2018;68(4):783\u201397.","journal-title":"J Hepatol"},{"issue":"1","key":"4228_CR10","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1148\/rg.25si055501","volume":"25","author":"CJ Simon","year":"2005","unstructured":"Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics. 2005;25(1):S69-83.","journal-title":"Radiographics"},{"issue":"17","key":"4228_CR11","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2217\/fon-2017-0736","volume":"14","author":"C Kim","year":"2018","unstructured":"Kim C. Understanding the nuances of microwave ablation for more accurate post-treatment assessment. Future Oncol. 2018;14(17):1755\u201364.","journal-title":"Future Oncol"},{"issue":"8","key":"4228_CR12","doi-asserted-by":"publisher","first-page":"S192","DOI":"10.1016\/j.jvir.2010.04.007","volume":"21","author":"MG Lubner","year":"2010","unstructured":"Lubner MG, Brace CL, Hinshaw JL, Lee FT Jr. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol. 2010;21(8):S192-203.","journal-title":"J Vasc Interv Radiol"},{"issue":"16","key":"4228_CR13","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.2217\/fon-2017-0061","volume":"13","author":"U Salati","year":"2017","unstructured":"Salati U, Barry A, Chou FY, Ma R, Liu DM. State of the ablation nation: a review of ablative therapies for cure in the treatment of hepatocellular carcinoma. Future Oncol. 2017;13(16):1437\u201348.","journal-title":"Future Oncol"},{"issue":"4","key":"4228_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000367747","volume":"4","author":"R Lencioni","year":"2015","unstructured":"Lencioni R, de Baere T, Martin RC, Nutting CW, Narayanan G. Image-guided ablation of malignant liver tumors: recommendations for clinical validation of novel thermal and non-thermal technologies - a Western perspective. Liver Cancer. 2015;4(4):208\u201314.","journal-title":"Liver Cancer"},{"issue":"6","key":"4228_CR15","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1007\/s00330-021-08497-2","volume":"32","author":"F De Cobelli","year":"2022","unstructured":"De Cobelli F, Calandri M, Della Corte A, Sirovich R, Gazzera C, Della Vigna P, et al. Multi-institutional analysis of outcomes for thermosphere microwave ablation treatment of colorectal liver metastases: the SMAC study. Eur Radiol. 2022;32(6):4147\u201359.","journal-title":"Eur Radiol"},{"issue":"4","key":"4228_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1055\/s-0035-1564811","volume":"32","author":"M Alonzo","year":"2015","unstructured":"Alonzo M, Bos A, Bennett S, Ferral H. The emprint ablation system with thermosphere technology: one of the newer next-generation microwave ablation technologies. Semin Intervent Radiol. 2015;32(4):335\u20138.","journal-title":"Semin Intervent Radiol"},{"issue":"1","key":"4228_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s13304-015-0288-1","volume":"67","author":"AM Ierardi","year":"2015","unstructured":"Ierardi AM, Mangano A, Floridi C, Dionigi G, Biondi A, Duka E, et al. A new system of microwave ablation at 2450\u00a0MHz: preliminary experience. Updates Surg. 2015;67(1):39\u201345.","journal-title":"Updates Surg"},{"key":"4228_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174346","author":"M Dijkstra","year":"2023","unstructured":"Dijkstra M, van der Lei S, Puijk RS, Schulz HH, Vos DJW, Timmer FEF, et al. Efficacy of thermal ablation for small-size (0\u20133\u00a0cm) versus intermediate-size (3\u20135\u00a0cm) colorectal liver metastases: results from the Amsterdam colorectal liver met registry (AmCORE). Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15174346.","journal-title":"Cancers"},{"issue":"6","key":"4228_CR19","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s11912-022-01248-6","volume":"24","author":"S Nieuwenhuizen","year":"2022","unstructured":"Nieuwenhuizen S, Dijkstra M, Puijk RS, Geboers B, Ruarus AH, Schouten EA, et al. Microwave ablation, radiofrequency ablation, irreversible electroporation, and stereotactic ablative body radiotherapy for intermediate size (3\u20135\u00a0cm) unresectable colorectal liver metastases: a systematic review and meta-analysis. Curr Oncol Rep. 2022;24(6):793\u2013808.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"4228_CR20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"4228_CR21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00270-020-02471-z","volume":"43","author":"L Crocetti","year":"2020","unstructured":"Crocetti L, de Baere T, Pereira PL, Tarantino FP. CIRSE standards of practice on thermal ablation of liver tumours. Cardiovasc Intervent Radiol. 2020;43(7):951\u201362.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4228_CR22","unstructured":"Services USDoHaH (2017). Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0 [Internet]. Available from. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 14 July 2021."},{"issue":"6","key":"4228_CR23","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s00270-020-02742-9","volume":"44","author":"P Hendriks","year":"2021","unstructured":"Hendriks P, Berkhout WEM, Kaanen CI, Sluijter JH, Visser IJ, van den Dobbelsteen JJ, et al. Performance of the Emprint and Amica microwave ablation systems in ex vivo porcine livers: sphericity and reproducibility versus size. Cardiovasc Intervent Radiol. 2021;44(6):952\u20138.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4228_CR24","unstructured":"IBM Corp. Released (2021). IBM SPSS Statistics for Windows, Version 28.0. Armonk, NY: IBM Corp."},{"key":"4228_CR25","unstructured":"RCT. R: A language and environment for statistical computing. R for Windows version 4.0.3. R Foundation for Statistical Computing, Vienna, Austria (2019). URL http:\/\/www.R-project.org\/."},{"issue":"2","key":"4228_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jso.26692","volume":"125","author":"E Berber","year":"2022","unstructured":"Berber E, Akbulut S. Assessment of a new 150 W single-antenna microwave ablation system in the treatment of malignant liver tumors: the first worldwide experience. J Surg Oncol. 2022;125(2):168\u201374.","journal-title":"J Surg Oncol"},{"key":"4228_CR27","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1016\/j.hpb.2023.05.272","volume":"25","author":"O Ergun","year":"2023","unstructured":"Ergun O, Akgun E, Isiktas G, Avci S, Berber E. Safety and efficacy of surgical liver tumor ablation using a 150\u00a0W microwave ablation system. HPB. 2023;25:S142.","journal-title":"HPB"},{"key":"4228_CR28","doi-asserted-by":"publisher","first-page":"153303382311852","DOI":"10.1177\/15330338231185277","volume":"22","author":"C Lanza","year":"2023","unstructured":"Lanza C, Carriero S, Ascenti V, Tintori J, Ricapito F, Lavorato R, et al. Percutaneous application of high power microwave ablation with 150\u00a0W for the treatment of tumors in lung, liver, and kidney: a preliminary experience. Technol Cancer Res Treat. 2023;22:15330338231185276.","journal-title":"Technol Cancer Res Treat"},{"issue":"11","key":"4228_CR29","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s00270-020-02584-5","volume":"43","author":"MT Winkelmann","year":"2020","unstructured":"Winkelmann MT, Gohla G, Kubler J, Weiss J, Clasen S, Nikolaou K, et al. MR-guided high-power microwave ablation in hepatic malignancies: initial results in clinical routine. Cardiovasc Intervent Radiol. 2020;43(11):1631\u20138.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"4228_CR30","first-page":"e89","volume":"26","author":"K Howk","year":"2015","unstructured":"Howk K. Consistent and predictable spherical ablation shape in both liver and lung: performance of the emprint ablation system with thermosphere technology in an in vivo porcine model. J Vasc Interv Radiol. 2015;26(5):e89\u201390.","journal-title":"J Vasc Interv Radiol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04228-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-025-04228-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04228-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:04:01Z","timestamp":1770131041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-025-04228-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4228"],"URL":"https:\/\/doi.org\/10.1007\/s00270-025-04228-y","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"For this type of study additional formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"For participation in the prospective AmCORE and HEPACARE registries were obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Consent for publication was obtained for every individual person\u2019s data included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}